Aveanna Healthcare Holdings Inc

AVAH remains in a Stage 2 advance with clear higher highs and higher lows confirming medium-term bullish asymmetry. After reaching extreme overbought levels, price has begun a pullback into the rising EMA band without clear exhaustion. Short-term timing is neutral amid this pullback, so we will stalk shallow pullbacks into the 9/21 EMA support for buy-on-dip participation.

• ↑Revenue surged 16.8% YoY to $590M in Q2 2025
• ↑Adjusted EBITDA rose 93.6% to $88.3M on cost initiatives
• ↓Operating cash only $4.3M and FCF negative $3.8M signal strain